Advantages of aspirin in the prevention of cardiovascular disease

https://doi.org/10.53730/ijhs.v6nS1.8201

Authors

  • Niladri M Associate Professor, Medical School, Akfa University, Uzbekistan.
  • Gayatri Devi Assistant Professor, Dr. Ram Manohar Lohia College of Pharmacy, Ghaziabad - 201206, Uttar Pradesh, India
  • Prateek Porwal Ph.D Research Scholar, Glocal School of Pharmacy, The Glocal University, Saharanpur, Uttar Pradesh, India
  • Jetendra Singh Chaudhary Associate Professor, Department of Pharmacy, Smt. Vidyawati College of Pharmacy, Jhansi - 284128, Uttar Pradesh, India
  • Simmi Gupta Department of Pharmaceutical Sciences, Sharda university, Greater Noida - 201306, Uttar Pradesh, India
  • Gyan Singh Ph.D Research Scholar, Glocal School of Pharmacy, The Glocal University, Saharanpur, Uttar Pradesh, India
  • Sunil Kumar Institute of Pharmacy, P.K. University, Thanra - 473665, Madhya Pradesh, India

Keywords:

Cardiovascular Disease, Aspirin, preventif

Abstract

Headache medicine treatment is perceived as a specialist in the adjunctive anticipation of cardiovascular occasions, and ongoing rules likewise characterize the job of aspirin in fundamental evasion. This review presents the fundamentals of anti-inflammatory medicine use as far as stream rules, makes sense of the elements that might influence the adequacy of ibuprofen treatment in the anticipation of cardiovascular illness, and momentarily surveys models for the reason increment. Proof backings the utilization of anti-inflammatory medicine in the deliberate and fundamental counteraction of cardiovascular occasions in specific populaces, yet commonsense models might need. Aspirin ought to be painstakingly thought to be as an essential and judicious cardiovascular infection anticipation technique in all grown-up patients in danger and requires further activity, like patient instruction, to guarantee appropriate use. Headache medicine is the premise of laid out antithrombotic treatment for patients with atherosclerosis, yet significant guideline is conflicting with its utilization in basic prophylaxis.

Downloads

Download data is not yet available.

References

Soni A. Aspirin use among the adult U.S. non institutionalized population, with and without indicators of heart disease, 2005. Statistical Brief #129 Agency for Healthcare Research and Quality, Medical Expenditure Panel Survey; Accessed February 6, 2013.

Fuster V, Sweeny JM. Aspirin: a historical and contemporary therapeutic overview. Circulation 2011;123:768–778.

Miner J, Hoffhines A. The discovery of aspirin’s antithrombotic effects Tex Heart Inst J 2007;34:179–186.

Dippel DW, Van Kooten F, Leebeek FW, van Vilet HH, Mehicevic A, Li SS, Koudstaal PJ. What is the lowest dose of aspirin for maximum suppression of in vivo thromboxane production after a transient ischemic attack or ischemic stroke? Cerebrovasc Dis 2004;17:296–302.

Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: a meta-analysis on 376,162 patients. Am J Med 2012;125:882–887.e1.

Vanwormer JJ, Greenlee RT, McBride PE, Peppard PE, Malecki KC, Che J, Nieto FJ. Aspirin for primary prevention of CVD: are the right people using it? J Fam Pract 2012;61:525533.

ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2:349–360

Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 2002; 324:71–86.

American Heart Association Website Aspirin and Heart Disease Accessed March 14, 2013.

Bell AD, Roussin A, Cartier R, Chan WS, Douketis JD, Gupta A, Kraw ME, Lindsay TF, Love MP, Pannu N, Rabasa-Lhoret R, Shuaib A, Teal P, Théroux P, Turpie AG, Welsh RC, Tanguay JF. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines Executive Summary. Can J Cardiol 2011; 27:208221

Centers for Disease Control and Prevention. National Center for Health Statistics Deaths and Mortality May 3, 2017.

Théroux P, Ouimet H, McCans J, Latour JG, Joly P, Lévy G, Pelletier E, Juneau M, Stasiak J, deGuise P, et al.. Aspirin, heparin, or both to treat acute unstable angina 1988; 319:1105–1111 doi: 10.1056/NEJM198810273191701

Baigent C, Sudlow C, Collins R and Peto R. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.BMJ. 2002; 324:71–86 doi: 10.1136/bmj.324.7329.71.

Patron C, Garcia Rodriguez LA, Lanolin R and Beignet C. Low-dose aspirin for the prevention of atherothrombosis N Eng J Med. 2005; 353:2373–2383. doi: 10.1056/NEJMra052717.

Bobbins-Domingo K. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement Ann Intern Med. 2016; 164:836–845. doi: 10.7326/M16-0577.

Published

31-05-2022

How to Cite

Niladri, M., Devi, G. ., Porwal, P., Chaudhary, J. S., Gupta, S., Singh, G., & Kumar, S. (2022). Advantages of aspirin in the prevention of cardiovascular disease. International Journal of Health Sciences, 6(S1), 12803–12811. https://doi.org/10.53730/ijhs.v6nS1.8201

Issue

Section

Peer Review Articles

Most read articles by the same author(s)

1 2 > >>